Caribbean News iBusiness iCommunity iHealth iLocal News iScience iTech iWorld News Manager's Choice News
F1 Oncology announces development milestone and $10M equity investment
From F1 Oncology Precision medicine-directed trial of AXL and ROR2 targeted conditionally active CAR-T cellular products to enroll patients with refractory, metastatic kidney cancer IMAGE: (PRNewsfoto/F1 Oncology) SHANGHAI and WEST PALM BEACH, Fla., Jan. 7, 2018 /PRNewswire/ — F1 Oncology, Inc.,…